At this time there are no effective methods to alter the disease course in 
Alzheimer's disease. All FDA approved interventions are for symptomatic relief 
only. However, it is an exciting time as many agents in development have 
theorhetical potential to impact the disease course. This review discusses some 
of the agents that have been in clinical trials, particularly those that affect 
amyloid processing. Some agents have failed while others still provide hope. 
Since amyloid is the peptide most closely linked to disease pathogenesis, it is 
possible that some of the anti-amyloid agents will impact the disease 
progression in a meaningful way.